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The biotherapeutics industry is aggressively targeting increases in product quality. It has been recently 
suggested that a 10x increase in robustness of product quality will be required in the next 5-10 years to meet the 
changing market forces of our industry1. This step-increase in quality will likely only be achieved by actively 
controlling product quality attributes in bioproduction processes, using techniques like model predictive control 
(MPC)2. Adoption of MPC of product quality attributes in bioproduction processes has been somewhat sluggish, 
despite the recent introduction of enabling technologies, such as aseptic auto samplers. One barrier for adoption 
of MPC is the current difficulty involved in developing MPC controllers. This difficulty stems from the fact that 
critical to quality process technologies like MPC must be adopted early in the drug development process to 
achieve consistent clinical material throughout the drug development process. There remains a need for a 
method to quickly and cheaply develop MPC strategies during early phase development for biomanufacturing 
processes. 
To address this barrier to early phase adoption of MPC, we developed a novel MPC development method which 
we believe is fast, inexpensive, and robust enough to be applied in early-stage bioreactor development 
programs. The proposed method measures the dynamic behavior of product quality attributes in response to 
modulations in media component concentrations. The method is enabled by a system which performs a series 
of automated, short (1-4 days), continuous experiments by using 
an automated perfusion apparatus to perform step-change 
experiments on the actual clone/media system proposed for the 
clinical bioreactor process. The resulting responses in product 
quality attributes are captured using automated analytical 
technologies, and the resulting dynamic quality data is used to 
create a model predictive controller in a systematic fashion. The 
result is a system which is capable of systematically generating 
model predictive controllers based on identified critical process 
parameters and the impacted critical quality attributes (CQAs). 
Here we show a proof of concept study, where all major 
components of the above described method were used to develop 
a model predictive controller for galactosylation of a monoclonal 
antibody, using galactose feed as the control handle. 
Experimental validation of the model used in the model predictive 
controller was demonstrated using a set of external fed-batch 
validation runs. We then demonstrated the controller’s ability to 
achieve a set galactosylation value in a simulated fed-batch 
process with variable galactose feeding (Figure 1). 
Using the method demonstrated here, we suggest that variation in product quality attributes can be actively 
controlled with much less process development effort than is typically used (e.g., batch DOE methodologies).  
This decrease in effort is achieved through heavy application of automation and short, continuous bioreactor 
studies. The ability to actively control product quality attributes using model predictive control and system 
identification strategies may catalyze wider adoption of active control of product quality attributes earlier in the 
development cycle, and we hope will accelerate adoption of MPC to achieve tighter CQAs in future 
biotherapeutics processes.  
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Figure 1 – Control chart of 
%galactosylation controlled by MPC-based 
feeding of galactose in a fed-batch process. 
 
